Decreased Beta-Adrenergic Receptors on Polymorphonuclear Leukocytes after Adrenergic Therapy

Authors:
  • SGStanley P. Galant
    Stanley P. Galant
  • LDLakshmi Duriseti
    Lakshmi Duriseti
  • SUSharon Underwood
    Sharon Underwood
  • PIPaul A. Insel
    Paul A. Insel
Publisher website
Google Scholar
Abstract
β-ADRENERGIC catecholamines, which modulate function of a variety of tissues, are assumed to act by initially binding to receptors on target-cell plasma membranes, thereby activating adenylate cyclase and stimulating generation of adenosine 3′:5′-monophosphate (cyclic AMP). In addition to activating adenylate cyclase, β-adrenergic agonists commonly have a second action — regulation of responsiveness of the target cells. Thus, continued treatment with such agonists often results in decreased cellular response. This self-regulation of target-cell responsiveness, variously termed refractoriness, desensitization and down-regulation, has been observed with catecholamines, as well as with a number of other hormonal agonists.1 2 3 For catecholamines, studies in several experimental . . .

This publication has 21 references indexed in Scilit: